Published in Int J Nanomedicine on December 09, 2011
A model for homeopathic remedy effects: low dose nanoparticles, allostatic cross-adaptation, and time-dependent sensitization in a complex adaptive system. BMC Complement Altern Med (2012) 0.89
Anti-HIV-1 nanotherapeutics: promises and challenges for the future. Int J Nanomedicine (2012) 0.88
Nonlinear effects of nanoparticles: biological variability from hormetic doses, small particle sizes, and dynamic adaptive interactions. Dose Response (2013) 0.87
Differential responses of osteoblasts and macrophages upon Staphylococcus aureus infection. BMC Microbiol (2014) 0.86
Cationic antimicrobial peptide LL-37 is effective against both extra- and intracellular Staphylococcus aureus. Antimicrob Agents Chemother (2012) 0.83
Selective targeting of melanoma by PEG-masked protein-based multifunctional nanoparticles. Int J Nanomedicine (2012) 0.82
Innovative pharmaceutical development based on unique properties of nanoscale delivery formulation. Nanoscale (2013) 0.82
Testing the nanoparticle-allostatic cross-adaptation-sensitization model for homeopathic remedy effects. Homeopathy (2013) 0.81
Advances in Integrative Nanomedicine for Improving Infectious Disease Treatment in Public Health. Eur J Integr Med (2013) 0.81
Exploring the potential role of tungsten carbide cobalt (WC-Co) nanoparticle internalization in observed toxicity toward lung epithelial cells in vitro. Toxicol Appl Pharmacol (2014) 0.80
Homeopathic medications as clinical alternatives for symptomatic care of acute otitis media and upper respiratory infections in children. Glob Adv Health Med (2013) 0.79
AuNPs for identification of molecular signatures of resistance. Front Microbiol (2014) 0.79
Integrative nanomedicine: treating cancer with nanoscale natural products. Glob Adv Health Med (2014) 0.79
Respiratory nanoparticle-based vaccines and challenges associated with animal models and translation. J Control Release (2015) 0.77
Targeting Multidrug-resistant Staphylococci with an anti-rpoA Peptide Nucleic Acid Conjugated to the HIV-1 TAT Cell Penetrating Peptide. Mol Ther Nucleic Acids (2016) 0.77
New hope for eradication of HIV from the body: the role of polymeric nanomedicines in HIV/AIDS pharmacotherapy. J Nanobiotechnology (2014) 0.76
Hydrophobic gentamicin-loaded nanoparticles are effective against Brucella melitensis infection in mice. Antimicrob Agents Chemother (2013) 0.76
Nanotoxicity: emerging concerns regarding nanomaterial safety and occupational hard metal (WC-Co) nanoparticle exposure. Int J Nanomedicine (2016) 0.75
Lactoferrin: A Natural Glycoprotein Involved in Iron and Inflammatory Homeostasis. Int J Mol Sci (2017) 0.75
Immunology of tuberculosis. Annu Rev Immunol (2001) 14.26
Epidemiology of hepatitis C virus infection. World J Gastroenterol (2007) 7.36
Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect (2011) 6.48
Nanoparticles in medicine: therapeutic applications and developments. Clin Pharmacol Ther (2007) 5.79
The changing epidemiology of resistance. J Antimicrob Chemother (2009) 5.13
Human brucellosis. Lancet Infect Dis (2007) 4.92
The coming era of nanomedicine. Am J Bioeth (2009) 4.67
Targeting of drugs and nanoparticles to tumors. J Cell Biol (2010) 4.07
Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B Biointerfaces (2009) 4.06
Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers. Proc Natl Acad Sci U S A (2008) 3.80
Brucella evades macrophage killing via VirB-dependent sustained interactions with the endoplasmic reticulum. J Exp Med (2003) 3.23
Rapid endo-lysosomal escape of poly(DL-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery. FASEB J (2002) 3.13
Infections caused by Gram-positive bacteria: a review of the global challenge. J Infect (2009) 3.06
LL-37, the only human member of the cathelicidin family of antimicrobial peptides. Biochim Biophys Acta (2006) 3.05
Understanding latent tuberculosis: a moving target. J Immunol (2010) 2.95
Inhibition of macrophage phagosome-lysosome fusion by Salmonella typhimurium. Infect Immun (1991) 2.83
How the parasitic bacterium Legionella pneumophila modifies its phagosome and transforms it into rough ER: implications for conversion of plasma membrane to the ER membrane. J Cell Sci (2001) 2.83
Hydrogel nanoparticles in drug delivery. Adv Drug Deliv Rev (2008) 2.71
Staphylococcus aureus as an intracellular pathogen: the role of small colony variants. Trends Microbiol (2009) 2.38
Current diagnosis and treatment of cutaneous and mucocutaneous leishmaniasis. Expert Rev Anti Infect Ther (2010) 2.35
Current advances in research and clinical applications of PLGA-based nanotechnology. Expert Rev Mol Diagn (2009) 2.35
Recent advances in the use of cell-penetrating peptides for medical and biological applications. Adv Drug Deliv Rev (2009) 2.18
Arginine-rich cell-penetrating peptides. FEBS Lett (2009) 2.17
Association of host cell endoplasmic reticulum and mitochondria with the Toxoplasma gondii parasitophorous vacuole membrane: a high affinity interaction. J Cell Sci (1997) 2.16
Characterization of nanoparticle uptake by endothelial cells. Int J Pharm (2002) 2.13
Chlamydia causes fragmentation of the Golgi compartment to ensure reproduction. Nature (2008) 2.04
Internalization of Staphylococcus aureus by cultured osteoblasts. Microb Pathog (1995) 2.03
What is nanomedicine? Nanomedicine (2005) 1.94
Staphylococcus aureus: new evidence for intracellular persistence. Trends Microbiol (2009) 1.92
Biodegradable nanoparticles for cytosolic delivery of therapeutics. Adv Drug Deliv Rev (2007) 1.92
A comparison of fluoroquinolones versus other antibiotics for treating enteric fever: meta-analysis. BMJ (2009) 1.91
Targeting nanoparticles to cancer. Pharmacol Res (2010) 1.88
The cell biology of infection by intracellular bacterial pathogens. Annu Rev Cell Dev Biol (1995) 1.81
Antibiotic consumption and link to resistance. Clin Microbiol Infect (2009) 1.81
Synthesis and characterization of PLGA nanoparticles. J Biomater Sci Polym Ed (2006) 1.79
Pegylated poly(lactide) and poly(lactide-co-glycolide) nanoparticles: preparation, properties and possible applications in drug delivery. Curr Drug Deliv (2004) 1.79
Poly(ethylene glycol)-modified nanocarriers for tumor-targeted and intracellular delivery. Pharm Res (2007) 1.77
Membrane association of hepatitis C virus nonstructural proteins and identification of the membrane alteration that harbors the viral replication complex. Antiviral Res (2003) 1.76
Viral entry mechanisms: cellular and viral mediators of herpes simplex virus entry. FEBS J (2009) 1.75
Bacterial gene amplification: implications for the evolution of antibiotic resistance. Nat Rev Microbiol (2009) 1.73
Adaptation of the Brucellae to their intracellular niche. Mol Microbiol (2004) 1.64
Future vaccination strategies against tuberculosis: thinking outside the box. Immunity (2010) 1.61
Vaccines against typhoid fever. Vaccine (2005) 1.61
Highlights in the discovery of antiviral drugs: a personal retrospective. J Med Chem (2010) 1.58
Current status and challenges of antiretroviral research and therapy. Antiviral Res (2009) 1.52
Promoting adherence to tuberculosis treatment. Bull World Health Organ (2007) 1.51
Targeted delivery of low molecular drugs using chitosan and its derivatives. Adv Drug Deliv Rev (2009) 1.46
Biodegradable polymeric microspheres and nanospheres for drug delivery in the peritoneum. J Biomed Mater Res A (2006) 1.44
Cathelicidin LL-37: a multitask antimicrobial peptide. Arch Immunol Ther Exp (Warsz) (2010) 1.43
The characteristics and mechanisms of uptake of PLGA nanoparticles in rabbit conjunctival epithelial cell layers. Pharm Res (2004) 1.42
Listeria monocytogenes transiently alters mitochondrial dynamics during infection. Proc Natl Acad Sci U S A (2011) 1.38
Mechanisms of internalization of Staphylococcus aureus by cultured human osteoblasts. Infect Immun (1999) 1.37
Management of drug-resistant tuberculosis. Int J Tuberc Lung Dis (2010) 1.36
Pharmacologic advances in the treatment and prevention of respiratory syncytial virus. Clin Infect Dis (2010) 1.36
HCV-related hepatocellular carcinoma: From chronic inflammation to cancer. Clin Immunol (2009) 1.35
Tuberculosis in humans and its epidemiology, diagnosis and treatment in the United States. Int J Tuberc Lung Dis (2010) 1.35
The effects of particle size and molecular targeting on the intratumoral and subcellular distribution of polymeric nanoparticles. Mol Pharm (2010) 1.35
The innate immune response to Aspergillus fumigatus. Microbes Infect (2009) 1.32
PEGylated polymers for medicine: from conjugation to self-assembled systems. Chem Commun (Camb) (2010) 1.31
Self-assembled cationic peptide nanoparticles as an efficient antimicrobial agent. Nat Nanotechnol (2009) 1.30
Cost of tuberculosis diagnosis and treatment from the patient perspective in Lusaka, Zambia. Int J Tuberc Lung Dis (2008) 1.30
Pathogenesis, immunology, and diagnosis of latent Mycobacterium tuberculosis infection. Clin Dev Immunol (2010) 1.29
Staphylococcus aureus host cell invasion and post-invasion events. Int J Med Microbiol (2009) 1.28
Current methods for attaching targeting ligands to liposomes and nanoparticles. J Pharm Sci (2004) 1.26
Dynamics of growth and dissemination of Salmonella in vivo. Cell Microbiol (2010) 1.23
Sustained cytoplasmic delivery of drugs with intracellular receptors using biodegradable nanoparticles. Mol Pharm (2004) 1.23
Targeted intracellular delivery of hydrophobic agents using mesoporous hybrid silica nanoparticles as carrier systems. Nano Lett (2009) 1.22
Recent advances in PEG-PLA block copolymer nanoparticles. Int J Nanomedicine (2010) 1.22
Pathogen-endoplasmic-reticulum interactions: in through the out door. Nat Rev Immunol (2006) 1.21
Biodegradable nanoparticles for targeted drug delivery in treatment of inflammatory bowel disease. J Pharmacol Exp Ther (2001) 1.21
Lipid nanocapsules: a new platform for nanomedicine. Int J Pharm (2009) 1.18
Targeted nanoparticles that deliver a sustained, specific release of Paclitaxel to irradiated tumors. Cancer Res (2010) 1.17
Translational nanomedicine: status assessment and opportunities. Nanomedicine (2009) 1.17
Bioinspired pH-responsive polymers for the intracellular delivery of biomolecular drugs. Bioconjug Chem (2003) 1.16
Intracellular Staphylococcus aureus. A mechanism for the indolence of osteomyelitis. J Bone Joint Surg Br (2003) 1.15
Intracellular trafficking of silicon particles and logic-embedded vectors. Nanoscale (2010) 1.15
Half-antibody functionalized lipid-polymer hybrid nanoparticles for targeted drug delivery to carcinoembryonic antigen presenting pancreatic cancer cells. Mol Pharm (2010) 1.14
Cytosol as battleground: ubiquitin as a weapon for both host and pathogen. Trends Cell Biol (2010) 1.13
Hyaluronic acid immobilized magnetic nanoparticles for active targeting and imaging of macrophages. Bioconjug Chem (2010) 1.12
Novel approaches in fighting herpes simplex virus infections. Expert Rev Anti Infect Ther (2009) 1.12
On the cellular localization of the components of the herpes simplex virus type 1 helicase-primase complex and the viral origin-binding protein. J Gen Virol (1992) 1.10
Intracellular trafficking of nuclear localization signal conjugated nanoparticles for cancer therapy. Eur J Pharm Sci (2009) 1.10
The evolution of HIV treatment guidelines: current state-of-the-art of ART. Antiviral Res (2009) 1.08
Functionalised gold nanoparticles for controlling pathogenic bacteria. Trends Biotechnol (2010) 1.07
Delivery systems to increase the selectivity of antibiotics in phagocytic cells. J Control Release (2007) 1.06
Limitations of antibiotic options for invasive infections caused by methicillin-resistant Staphylococcus aureus: is combination therapy the answer? J Antimicrob Chemother (2010) 1.06
Candidosis, a new challenge. Clin Dermatol (2010) 1.04
Uptake and intracellular fate of disulfide-bonded polymer hydrogel capsules for Doxorubicin delivery to colorectal cancer cells. ACS Nano (2010) 1.03
Liposome-encapsulated aminoglycosides in pre-clinical and clinical studies. J Antimicrob Chemother (2001) 1.03
Regulation between survival, persistence, and elimination of intracellular mycobacteria: a nested equilibrium of delicate balances. Microbes Infect (2010) 1.01
Intracellular killing of Brucella melitensis in human macrophages with microsphere-encapsulated gentamicin. J Antimicrob Chemother (2006) 1.01
Why do patients fail HIV therapy? Int J Clin Pract (2007) 1.00
Hepatitis C virus: molecular biology & current therapeutic options. Indian J Med Res (2010) 0.99
Amphotericin B-entrapping lipid nanoparticles and their in vitro and in vivo characteristics. Eur J Pharm Sci (2009) 0.96
Cyclodextrin-insulin complex encapsulated polymethacrylic acid based nanoparticles for oral insulin delivery. Int J Pharm (2006) 0.95
Review and current status of emulsion/dispersion technology using an internal gelation process for the design of alginate particles. J Microencapsul (2006) 0.94
A new insight into hepatitis C vaccine development. J Biomed Biotechnol (2010) 0.94
New drug delivery systems based on chitosan. Curr Drug Discov Technol (2008) 0.93
Visiting the cell biology of Salmonella infection. Microbes Infect (2010) 0.93
Selective targeting of green fluorescent nanodiamond conjugates to mitochondria in HeLa cells. J Biophotonics (2009) 0.92
Interleukin 12 a key immunoregulatory cytokine in infection applications. Int J Mol Sci (2010) 1.41
Tunable drug loading and release from polypeptide multilayer nanofilms. Int J Nanomedicine (2009) 0.95
Cefazolin embedded biodegradable polypeptide nanofilms promising for infection prevention: a preliminary study on cell responses. J Orthop Res (2010) 0.89
Additive effects of exogenous IL-12 supplementation and antibiotic treatment in infection prophylaxis. J Orthop Res (2011) 0.89
Kaempferol nanoparticles achieve strong and selective inhibition of ovarian cancer cell viability. Int J Nanomedicine (2012) 0.86
Chaetoglobosin K inhibits tumor angiogenesis through downregulation of vascular epithelial growth factor-binding hypoxia-inducible factor 1α. Anticancer Drugs (2013) 0.86
pH-controlled drug loading and release from biodegradable microcapsules. Nanomedicine (2008) 0.86
Polypeptide nanocoatings for preventing dental and orthopaedic device-associated infection: pH-induced antibiotic capture, release, and antibiotic efficacy. J Biomed Mater Res B Appl Biomater (2009) 0.85
Fluoride decreased osteoclastic bone resorption through the inhibition of NFATc1 gene expression. Environ Toxicol (2012) 0.85
Biomimetic nanostructured materials: inherent reversible stabilization of polypeptide microcapsules. Langmuir (2005) 0.84
Cationic antimicrobial peptide LL-37 is effective against both extra- and intracellular Staphylococcus aureus. Antimicrob Agents Chemother (2012) 0.83
Fine tuning of physical properties of designed polypeptide multilayer films by control of pH. Biotechnol Prog (2006) 0.78
Unique antimicrobial effects of platelet-rich plasma and its efficacy as a prophylaxis to prevent implant-associated spinal infection. Adv Healthc Mater (2013) 0.78
Polypeptide multilayer film co-delivers oppositely-charged drug molecules in sustained manners. Biomacromolecules (2010) 0.77
PRP as a new approach to prevent infection: preparation and in vitro antimicrobial properties of PRP. J Vis Exp (2013) 0.77
Advances in polyelectrolyte multilayer nanofilms as tunable drug delivery systems. Nanotechnol Sci Appl (2009) 0.77
Amino acid-functionalized ionic liquid solid sorbents for post-combustion carbon capture. ACS Appl Mater Interfaces (2013) 0.77
An assessment of the relationship between excess fluoride intake from drinking water and essential hypertension in adults residing in fluoride endemic areas. Sci Total Environ (2012) 0.77
Tungsten Carbide-Cobalt Nanoparticles Induce Reactive Oxygen Species, AKT, ERK, AP-1, NF-κB, VEGF, and Angiogenesis. Biol Trace Elem Res (2015) 0.76
Nanoencapsulating living biological cells using electrostatic layer-by-layer self-assembly: platelets as a model. J Mater Res (2011) 0.75
Mechanisms Underlying Endothelin-1 Level Elevations Caused by Excessive Fluoride Exposure. Cell Physiol Biochem (2016) 0.75
Perturbation of nanoscale structure of polypeptide multilayer thin films. Langmuir (2005) 0.75
CO2 capture properties of lithium silicates with different ratios of Li2O/SiO2: an ab initio thermodynamic and experimental approach. Phys Chem Chem Phys (2013) 0.75